Bridgebio Oncology TherapeutBBOT
13F holders, Q4 2024 (December 31)At the end of Q4 2024, 32 institutions reported holding Bridgebio Oncology Therapeut (BBOT) in their 13F filings, up 1 from Q3 2024. 2 opened new positions and 2 sold out. The largest holders were Cormorant Asset Management, LP ($30.5M), BlackRock, Inc. ($15.7M) and Adage Capital Partners Gp, L.L.C. ($14.7M). 3 famous investors held it, including George Soros (0.1% of Soros Fund Management's portfolio), Ken Griffin (0.0% of Citadel Advisors's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Bridgebio Oncology Therapeut
- Filed as
- HELIX ACQUISITION CORP II (Q4 2024)
- CUSIP
- G4444H101
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $520K |
| Exits | 2 | $1.3M |
All 13F filers, Q3 2024 → Q4 2024: 109,450 shares bought and 160,926 shares sold, net −51,476 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 32 holders
| Cormorant Asset Management, LP | 1.68% | No change | 2,909,000 | $30.5M |
| BlackRock, Inc. | 0.00% | Reduce -0.1% | 1,498,865 | $15.7M |
| Adage Capital Partners Gp, L.L.C. | 0.03% | No change | 1,400,000 | $14.7M |
| Citadel Advisors | 0.01% | Add +0.5% | 1,339,670 | $14.1M |
| Millennium Management | 0.01% | Add +1.1% | 1,142,302 | $12.0M |
| T. Rowe Price Associates Inc. | 0.00% | Reduce -3.5% | 1,087,771 | $11.4M |
| Sculptor Capital LP | 0.18% | No change | 705,000 | $7.4M |
| Farallon Capital Management, L.L.C. | 0.03% | No change | 600,000 | $6.3M |
| Silverarc Capital Management, LLC | 1.21% | No change | 513,369 | $5.4M |
| Great Point Partners LLC | 2.47% | No change | 500,000 | $5.3M |
| Commodore Capital LP | 0.38% | No change | 500,000 | $5.3M |
| Perceptive Advisors LLC | 0.15% | No change | 500,000 | $5.3M |
| Soros Fund Management | 0.13% | Add +0.0% | 475,114 | $5.0M |
| ADAR1 Capital Management, LLC | 0.90% | No change | 404,138 | $4.2M |
| T. Rowe Price Investment Management, Inc. | 0.00% | Add +0.7% | 400,247 | $4.2M |
| Laurion Capital Management LP | 0.20% | No change | 300,000 | $3.1M |
| Harraden Circle Investments, LLC | 2.32% | — | 257,226 | $2.7M |
| Octagon Capital Advisors LP | 0.45% | No change | 250,000 | $2.6M |
| Affinity Asset Advisors, LLC | 0.45% | No change | 250,000 | $2.6M |
| Stempoint Capital LP | 0.53% | Add +0.5% | 200,900 | $2.1M |
| Two Sigma Investments, LP | 0.00% | No change | 189,285 | $2.0M |
| Decagon Asset Management LLP | 0.90% | — | 186,454 | $2.0M |
| Wellington Management Group LLP | 0.00% | Reduce -0.0% | 184,590 | $1.9M |
| Acuta Capital Partners, LLC | 1.91% | No change | 180,945 | $1.9M |
| TD Asset Management Inc | 0.00% | No change | 144,772 | $1.5M |
| Woodline Partners LP | 0.01% | No change | 103,247 | $1.1M |
| Moore Capital Management, LP | 0.02% | No change | 100,000 | $1.1M |
| Toronto Dominion Bank | 0.00% | New | 49,500 | $520K |
| UBS Group AG | 0.00% | Add +166319.0% | 34,948 | $367K |
| Gritstone Asset Management LLC | 0.28% | — | 24,666 | $259K |
| Geode Capital Management, LLC | 0.00% | Add +22.1% | 13,274 | $139K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 1 | $10 |
"% of holder's portfolio" is BBOT's weight in each manager's 13F, not the share of Bridgebio Oncology Therapeut the manager owns.